Figure 1
Induction of chronic pancreatitis in mice treated with NOD1 ligand and a low-dose cerulein. (a) Experimental protocol (Left): C57BL6 mice were administered FK565 (NOD1 ligand, 50 μg) alone (n=7), a low-dose cerulein (20 μg kg−1) for a total of three times (n=8), or FK565 followed by a low-dose cerulein (20 μg kg−1) for a total of three times (n=10). Mice received each regimen twice a week for a total of 14 times and then sera and pancreatic tissues were obtained. Serum levels of amylase, pathological scores of the pancreas, pancreatic weight, and the numbers of pancreatic α-SMA+ cells per high power fields obtained from mice 3 h after the last injection of cerulein. Results are expressed as mean±s.e.m. and are a pool of two independent experiments. *P<0.05, **P<0.01 as compared with cerulein alone. (b) Representative picture of the pancreas tissue stained with hematoxylin and eosin (H&E) staining, anti-CD3 Ab, anti-CD11b Ab, anti-SMA Ab, Sirius red, and anti-fibronectin Ab. Magnification × 400. Ab, antibody; NOD1, nucleotide-binding oligomerization domain 1.
